Idogen’s cash is estimated to last until June and the company is currently working with various financing alternatives.
Idogen’s work with capitalization is not yet finalized. The cash is estimated to last until the end of June. Idogen is working in parallel with various financing alternatives. ”We are working with several alternatives but have not yet reached a conclusion. In order to make the cash last longer, we have reduced costs as well as sold instruments and consumables. In our judgement, the cash will last until end of June. We are, as it should be in these type of situations, in dialogue with both our Certified Advisor as we all as with Nasdaq” says Christina Herder, acting CEO.